Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate. Methods: Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer treatment at two tertiary care hospitals in Korea were identified. For each patient, the tumor volume doubling time (TVDT) of HCC was calculated by comparing tumor volumes between serial imaging studies. Clinical and laboratory data were obtained from the medical records of the patients. Results: The median TVDT was 85.7 days, with a range of 11 to 851.2 days. Multiple linear regression revealed that the initial tumor diameter (a tumor factor) and the etiology of chronic liver disease (a host factor) were significantly associated with the TVDT. The TVDT was shorter when the initial tumor diameter was smaller, and was shorter in HCC related to hepatitis B virus (HBV) infection than in HCC related to hepatitis C virus (HCV) infection (median, 76.8 days vs. 137.2 days; P=0.0234). Conclusions: The etiology of chronic liver disease is a host factor that may significantly affect the growth rate of early-stage HCC, since HBV-associated HCC grows faster than HCV-associated HCC. (Clin Mol Hepatol 2015;21:279-286)
Abstract
Background/Aims: The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate. Methods: Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer treatment at two tertiary care hospitals in Korea were identified. For each patient, the tumor volume doubling time (TVDT) of HCC was calculated by comparing tumor volumes between serial imaging studies. Clinical and laboratory data were obtained from the medical records of the patients. Results: The median TVDT was 85.7 days, with a range of 11 to 851.2 days. Multiple linear regression revealed that the initial tumor diameter (a tumor factor) and the etiology of chronic liver disease (a host factor) were significantly associated with the TVDT. The TVDT was shorter when the initial tumor diameter was smaller, and was shorter in HCC related to hepatitis B virus (HBV) infection than in HCC related to hepatitis C virus (HCV) infection (median, 76.8 days vs. 137.2 days; P=0.0234). Conclusions: The etiology of chronic liver disease is a host factor that may significantly affect the growth rate of early-stage HCC, since HBV-associated HCC grows faster than HCV-associated HCC. (Clin Mol Hepatol 2015;21:279-286)
참고문헌 (36)
- Daniele B, "Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma", Gastroenterology, 127, pp.S108~S112 (2004)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- McMahon BJ, "Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B : a 16-year population-based study", Hepatology, 32, pp.842~846 (2000)
- Wong LL, "Improved survival with screening for hepatocellular carcinoma", Liver Transpl, 6, pp.320~325 (2000)
- Zhang BH, "Randomized controlled trial of screening for hepatocellular carcinoma", J Cancer Res Clin Oncol, 130, pp.417~422 (2004)
- Kudo M, "Japan’s successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance", Liver cancer, 1, pp.141~143 (2012)
- Kudo M, "Early hepatocellular carcinoma : definition and diagnosis", Liver cancer, 2, pp.69~72 (2013)
- Teo EK, "Hepatocellular carcinoma : an Asian perspective", Dig Dis, 19, pp.263~268 (2001)
- Della Corte C, "Surveillance for hepatocellular carcinoma", Semin Oncol, 39, pp.384~398 (2012)
- Sherman M., "Hepatocellular carcinoma: screening and staging", Clin Liver Dis, 15, pp.323~334 (2011)
- Han KH, "Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months : a 15-year prospective study", J Clin Gastroenterol, 47, pp.538~544 (2013)
- Kim DY, "Epidemiology and surveillance of hepatocellular carcinoma", Liver cancer, 1, pp.2~14 (2012)
- Kim Y, "The role of the microenvironment in tumor growth and invasion", Prog Biophys Mol Biol, 106, pp.353~379 (2011)
- Yoshino M, "Growth kinetics of hepatocellular carcinoma", Jpn J Clin Oncol, 13, pp.45~52 (1983)
- Sheu JC, "Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications", Gastroenterology, 89, pp.259~266 (1985)
- Ebara M, "Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis", Gastroenterology, 90, pp.289~298 (1986)
- Okazaki N, "Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time", Cancer, 63, pp.2207~2210 (1989)
- Sadek AG, "Early hepatocellular carcinoma that develops within macroregenerative nodules : growth rate depicted at serial MR imaging", Radiology, 195, pp.753~756 (1995)
- Ebara M, "Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients", Hepatogastroenterology, 45(3), pp.1214~1220 (1998)
- Kubota K, "Growth rate of primary single hepatocellular carcinoma : determining optimal screening interval with contrast enhanced computed tomography", Dig Dis Sci, 48, pp.581~586 (2003)
- Taouli B, "Growth rate of hepatocellular carcinoma : evaluation with serial computed tomography or magnetic resonance imaging", J Comput Assist Tomogr, 29, pp.425~429 (2005)
- Park Y, "Growth rate of new hepatocellular carcinoma after percutaneous radiofrequency ablation : evaluation with multiphase CT", AJR Am J Roentgenol, 191, pp.215~220 (2008)
- Corrao G, "A meta-analysis of alcohol consumption and the risk of 15 diseases", Prev Med, 38, pp.613~619 (2004)
- Schwartz M, "A biomathematical approach to clinical tumor growth", Cancer, 14, pp.1272~1294 (1961)
- Kim W, "Comparison of proteome between hepatitis B virus-and hepatitis C virusassociated hepatocellular carcinoma", Clin Cancer Res, 9, pp.5493~5500 (2003)
- Farazi PA, "Hepatocellular carcinoma pathogenesis : from genes to environment", Nat Rev Cancer, 6, pp.674~687 (2006)
- Iizuka N, "Molecular signature in three types of hepatocellular carcinoma with different viral origin by oligonucleotide microarray", Int J Oncol, 24, pp.565~574 (2004)
- Iizuka N, "Comparison of gene expression profiles between hepatitis B virus-and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method", Cancer Res, 62, pp.3939~3944 (2002)
- Lee C, "Distinct expression patterns in hepatitis B virus-and hepatitis C virus-infected hepatocellular carcinoma", World J Gastroenterol, 14, pp.6072~6077 (2008)
- Kojiro M., "Pathology of Hepatocellular Carcinoma" (2006), Wiley-Blackwell
- Arzumanyan A, "Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma", Nat Rev Cancer, 13, pp.123~135 (2013)
- Rodriguez-Brenes IA, "Tumor growth dynamics : insights into evolutionary processes", Trends Ecol Evol, 28, pp.597~604 (2013)
- Guiot C, "Does tumor growth follow a"universal law"?", J Theor Biol, 225, pp.147~151 (2003)
- Reuss R, "Intracellular delivery of carbohydrates into mammalian cells through swelling-activated pathways", J Membr Biol, 200, pp.67~81 (2004)
- Weedon Fekjaer H, "Breast cancer tumor growth estimated through mammography screening data", Breast Cancer Res, 10, pp.R41~ (2008)
- Forner A, "Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis : Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma", Hepatology, 47, pp.97~104 (2008)